John G Ullman & Associates Inc. Has $2.36 Million Stake in Zimmer Biomet Holdings, Inc. $ZBH

Key Points

• John G Ullman & Associates Inc. reduced its stake in Zimmer Biomet Holdings, Inc. by 14.3%, owning $2.36 million worth of shares after selling 4,300 shares.
• The company has announced a quarterly dividend of $0.24 per share, with an annualized yield of 0.9%, payable on October 31st.
• Zimmer Biomet reported a quarterly earnings per share (EPS) of $2.07, exceeding analysts' estimates, with a projected FY 2025 EPS guidance between $8.100 and $8.300.

John G Ullman & Associates Inc. trimmed its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 14.3% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 25,850 shares of the medical equipment provider's stock after selling 4,300 shares during the period. John G Ullman & Associates Inc.'s holdings in Zimmer Biomet were worth $2,358,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. Garde Capital Inc. acquired a new stake in shares of Zimmer Biomet in the first quarter valued at approximately $29,000. Washington Trust Advisors Inc. acquired a new stake in shares of Zimmer Biomet in the first quarter valued at approximately $30,000. Columbia River Financial Group LLC acquired a new stake in shares of Zimmer Biomet in the first quarter valued at approximately $30,000. Accent Capital Management LLC acquired a new stake in shares of Zimmer Biomet in the first quarter valued at approximately $35,000. Finally, Cullen Frost Bankers Inc. lifted its position in shares of Zimmer Biomet by 1,452.4% in the first quarter. Cullen Frost Bankers Inc. now owns 326 shares of the medical equipment provider's stock valued at $37,000 after buying an additional 305 shares during the last quarter. 88.89% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, SVP Lori Winkler sold 1,500 shares of the company's stock in a transaction dated Monday, September 8th. The stock was sold at an average price of $104.15, for a total transaction of $156,225.00. Following the sale, the senior vice president owned 6,833 shares in the company, valued at $711,656.95. This represents a 18.00% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 1.39% of the company's stock.

Zimmer Biomet Price Performance

Zimmer Biomet stock opened at $102.00 on Friday. The stock's fifty day moving average price is $101.74 and its two-hundred day moving average price is $97.78. Zimmer Biomet Holdings, Inc. has a one year low of $89.22 and a one year high of $114.72. The company has a debt-to-equity ratio of 0.54, a current ratio of 1.87 and a quick ratio of 0.96. The firm has a market cap of $20.21 billion, a PE ratio of 24.82, a price-to-earnings-growth ratio of 2.35 and a beta of 0.67.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The medical equipment provider reported $2.07 EPS for the quarter, topping analysts' consensus estimates of $1.98 by $0.09. Zimmer Biomet had a return on equity of 12.76% and a net margin of 10.51%.The firm had revenue of $2.08 billion for the quarter, compared to analyst estimates of $2.06 billion. During the same quarter last year, the company earned $2.01 EPS. The company's revenue was up 7.0% on a year-over-year basis. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. As a group, research analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Tuesday, September 30th will be paid a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a yield of 0.9%. The ex-dividend date is Tuesday, September 30th. Zimmer Biomet's dividend payout ratio (DPR) is 23.36%.

Analysts Set New Price Targets

Several analysts recently weighed in on ZBH shares. Roth Capital reissued a "buy" rating on shares of Zimmer Biomet in a report on Thursday, August 7th. Stifel Nicolaus lifted their price target on Zimmer Biomet from $115.00 to $118.00 and gave the stock a "buy" rating in a report on Friday, September 19th. Raymond James Financial lifted their price target on Zimmer Biomet from $104.00 to $113.00 and gave the stock an "outperform" rating in a report on Friday, August 8th. Redburn Partners set a $130.00 price target on Zimmer Biomet in a report on Thursday, September 18th. Finally, BTIG Research lifted their price target on Zimmer Biomet from $118.00 to $122.00 and gave the stock a "buy" rating in a report on Monday, October 13th. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, eight have issued a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average target price of $111.94.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.

Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.